MedTrace Logo

CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements

NCT01313910 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2017-06-15

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to see if ImmunoLin® will reduce the frequency of bowel movements and gastrointestinal (GI) symptoms in HIV volunteers with persistent GI symptoms. The study will also examine the effect of ImmunoLin® on the bacteria in the gut and the immune system in gut tissue as well as in the blood.

Conditions

Interventions

DIETARY_SUPPLEMENT

Immunolin®

Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks

Sponsors & Collaborators

  • Proliant Health & Biologicals

    collaborator UNKNOWN

  • University of California, Davis

    lead OTHER

Principal Investigators

  • David M. Asmuth, MD · University of California, Davis Int Med: ID

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01313910 on ClinicalTrials.gov